SURF News and Press, Surface Oncology Inc. From 01/27/20

Gainers: XLRN   +79.4% . SURF   +17.2% . DESP   +8.7% . KBWB   +5.8% . BCRX   +4.4% . More news on: Acceleron Pharma Inc., Surface Oncology, Inc., Despegar.com, Corp., Stocks on the move, , , News on ETFs Read more ...

Company focuses efforts and resources on advancing SRF617 and SRF388; Implements strategic restructuring Initial clinical updates for SRF617 and SRF388 expected by the end of 2020 Extends current cash runway into 2022 CAMBRIDGE, Mass., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Surfac...

Cancer drug company Forty Seven 's  (NASDAQ: FTSV) stock price continues to climb higher following the December release of positive data from a Phase 1 clinical trial involving its lead cancer immunotherapy compound, magrolimab. The stock is up more than 200% since early last month. These...

Investment Thesis Last week, in my research note on direct Trillium (TRIL) rival, Forty Seven (FTSV), I argued that Forty Seven was the pick of the immunology companies developing CD47 antibodies to treat various forms of cancer - including hematologic malignancies, diffuse large B-cell ly...

Forty Seven Inc. (FTSV) had achieved positive results from an early-stage study in treatment-naive patients with high-risk myelodysplastic syndrome ((MDS)) and acute myeloid leukemia ((AML)). The positive results were obtained using the company's drug magrolimab in combination with Vidaza (a...

Dosing is underway in a Phase 2 registrational trial in China evaluating I-Mab Biopharma's TJ202/MOR202, a fully human monoclonal antibody targeting a protein found on the surface of cancer cells called CD38, in patients with relapsed/refractory multiple myeloma (MM). The company in-lice...

CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Surface Oncology  (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palomb...

Surface Oncology ( SURF -22.3% ) secured a debt financing facility for up to $25M from K2 HealthVentures More news on: Surface Oncology, Inc., Healthcare stocks news, Read more ...

Gainers:  JanOne (NASDAQ: JAN ) +103% . More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Peck Company Holdings, Inc., Stocks on the move, Read more ...

CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Surface Oncology  (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced it has secured a debt financing facility for up to $25 mil...